Comparison of Pulmicort®pMDI plus Nebuhaler®and Pulmicort®Turbuhaler®in asthmatic patients with dysphonia  by CROMPTON, G.K. et al.
Comparison of Pulmicort1 pMDI plus
Nebuhaler1 and Pulmicort1 Turbuhaler1
in asthmatic patients with dysphonia
G. K. CROMPTON*, R. SANDERSON{ , M. H. DEWAR*, S. P. MATUSIEWICZ*, A. C. W. S. NING{,
A. H. JAMIESON{, A. MCLEAN{ AND A. P. GREENING*
*Respiratory Medicine Unit, Western General Hospital, Edinburgh, {St John’s Hospital, Livingston,
{AstraZeneca Clinical Research Edinburgh, U.K.
Background. Dysphonia is a known local adverse eect of inhaled corticosteroids. This symptom was investigated
by laryngoscopy and assessment in a voice laboratory. The eects of changing the treatment of patients with
dysphonia, reported whilst using the pMDI, to pMDI plus Nebuhaler1 or Tubuhaler1 was also assessed.
Methods. Seventy-two patients reporting dysphonia and taking inhaled steroids from a pMDI entered a 12-week,
open, parallel group study. Fifty-one completed the study per protocol; 26 in the Nebuhaler group [21 female, mean
age 57 years (22–77)] and 25 in the Turbuhaler1 group [18 female, mean age 58 years (21–81)]. A dysphonia diary
card was completed weekly. Voice laboratory assessments and laryngoscopy were performed on entry and at 12
weeks.
Results. There were no dierences in voice laboratory data, laryngoscopic evidence of disordered glottic closure
and diary data between the two groups at 12 weeks. At study entry laryngoscopic appearances were normal in
almost half the patients. Vocal cord bowing was rarely seen. Glottic closure changed in nine patients during the
study period, but there was no correlation with voice symptoms. The trend of symptomatic improvement of voice
status in the Turbuhaler1 group did not correlate with voice laboratory assessments and laryngoscopic evidence of
disordered glottic closure.
After 4 weeks, 40% of patients using Turbuhaler1 and 8% in the Nebuhaler1 group scored their voice status as
better (P<0?02) but there was no significant dierence between the two groups at 12 weeks (Turbuhaler1 52%,
Nebuhaler1 23%, P=0?08).
Conclusion. This study does not support the view that dysphonia in asthmatics inhaling corticosteroids is usually
caused by myopathic bowing of the vocal cord muscles.
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The most common local adverse eects of inhaled
corticosteroid therapy are oropharyngeal candidiasis and
dysphonia. Candidiasis is rarely a major clinical problem,
and can usually be treated eectively without having to stop
inhaled treatment. Dysphonia, however, tends to persist
and, if severe, the only remedy is discontinuation of inhaled
corticosteroids. Unfortunately, it usually recurs if treatmentReceived 8 July and accepted 25 November 1999.
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0954-6111/00/050448+06 $35?00/0is restarted (1). Voice problems have been reported to occur
in 30–50% of patients being treated with an inhaled
corticosteroid administered by pressurized metered dose
inhaler (pMDI) (2,3). It has been reported that of 14
patients with corticosteroid-induced dysphonia, nine had
bilateral adductor cord deformity with bowing of the cords
on phonation (4). Although this was claimed to be
‘characteristic’, three of the remaining patients were
considered to have candidiasis as the sole cause of
dysphonia, and in another two the voice problem was
thought to be psychogenic. Nevertheless, it has been
generally accepted that inhaled corticosteroid-induced
dysphonia is caused by myopathic bowing of the vocal
cords.
Engel et al. (5) suggested that the frequency of dysphonia
was reduced by using a dry powder device (Turbuhaler1)# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Number of patients on each dose of Pulmicort1
Daily dose (mg) Turbuhaler1 Nebuhaler1
800 5 3
1200 6 6
1600 7 10
1800 1 0
2000 4 5
2400 2 2
PMDI PLUS NEBUHALER AND TURBUHALER IN ASTHMATICS WITH DYSPHONIA 449and subsequently it was reported that changing the delivery
system from pMDI and spacer to Turbuhaler1 substan-
tially decreased the incidence of local adverse eects of
inhaled corticosteroids, including voice problems (6).
Theoretically, there are a number of possible reasons why
a dry powder inhaler might be associated with less
dysphonia than pressurized aerosol corticosteroid therapy.
Inhalation through a device with a higher airflow resistance
than the pMDI results in a change in the shape of the oro-
pharynx and position of both the false and vocal cords.
Drug deposition in the region of the vocal cords may,
therefore, be dierent with a high inspiratory flow
resistance device compared with a low resistance device.
This study was designed to correlate voice quality, as
assessed by objective measurements made in a voice
laboratory, with vocal cord abnormalities detected by
laryngoscopy of patients reporting dysphonia during
pMDI-administered inhaled corticosteroid treatment, and
also to assess the eect on dysphonia of a change of delivery
system from the pMDI to a dry powder device (Turbu-
haler1) or a pMDI plus large volume spacer (Nebuhaler1).
Methods
SUBJECTS
Outpatients aged 18 years or more being treated with an
inhaled corticosteroid preparation in a dose of 4800 mg/
day by pMDI were selected if they had a dysphonia severity
score of42, as defined by an interview-based questionnaire
(3). Dysphonia severity was scored: 0=none, 1=mild, 2=
moderate, 3 = severe, or 4 = total loss of voice. Patients
were excluded if, during the 4 weeks prior to study entry,
there had been any change of inhaled corticosteroid
therapy, a respiratory tract infection or if in the investiga-
tor’s opinion the dysphonia was not associated with inhaled
corticosteroid therapy. The study was approved by the
Lothian Research Ethics Committee and written informed
consent was obtained from all patients.
STUDY DESIGN
This was an open, randomized, parallel group study of 12
weeks’ duration, during which budesonide was inhaled
twice daily via Turbuhaler1 or pMDI plus Nebuhaler1.
The pMDI and Turbuhaler1 used delivered 200 g per
actuation/dose. The dose of budesonide prescribed was that
which corresponded most closely to the pre-trial dose of
budesonide or beclomethasone dipropionate (Table 1). The
randomization schedule was computer-generated, using
blocks of eight. During the study no inhaled corticosteroids
other than study inhalers were allowed. Patients continued
with their usual bronchodilator inhalers.
ASSESSMENTS
Patients were assessed on three occasions during the study:
at study entry and after 4 and 12 weeks (visits 1, 2 and 3,respectively). At each visit dysphonia severity and fre-
quency was assessed by questionnaire, and forced expira-
tory volume in 1 sec (FEV1) and forced vital capacity
(FVC) were measured. At visits 2 and 3 the change in voice
status was assessed by questionnaire (worse, the same, or
better). All patients were assessed in the voice laboratory,
and indirect fibreoptic laryngoscopy was performed at
study entry and at 12 weeks. In the voice laboratory, the
Visi-Pitch IBM interface system was used to assess
‘fundamental frequency’ (Hz), ‘frequency perturbation or
jitter’ (%) and ‘maximum phonation time’ (sec). The
‘phonation quotient’ was calculated by dividing FVC by
maximum phonation time. The ‘percentage voiced’ was
measured as the percentage of phonation time a vowel was
actually sounded (normal = 100%). Semitone (pitch
range)—the number of semitones over which the frequency
changes whilst an ascending and descending scale is sung—
was also measured.
Indirect fibreoptic laryngoscopy was performed, with the
examiner being blind to the patients’ treatment, using 4%
lignocaine if necessary. Vocal cord closure was graded as:
complete, anterior chink, irregular, bowing, posterior
chink, hour glass and incomplete (Fig. 1). The cords were
also examined for evidence of candidiasis, inflammation
and any other abnormality.
Dysphonia severity scores were recorded weekly using
the scoring system described above plus a frequency score
of voice problems using the range: 0 = never, 1 =
occasionally, 2 = most of the time, 3 = all of the time.
STATISTICAL METHODS
A sample size of 60 (30 in each group) permitted detection
of a treatment-induced change in the incidence of dyspho-
nia from 90% to 60% (a=0?05, b=0?2). The primary
variable was the change from baseline (visit 1) in the
incidence of dysphonia as assessed by questionnaire. Some
categories for questions had frequencies too small to permit
statistical analysis, and thus question response categories
were combined as follows:
Frequency: ‘Never’ with and ‘Most’ with
‘occassionally’ ‘all of the time’
Severity: None ‘Mild’ with and ‘Severe’ with
‘moderate’ ‘total loss’
The stratified Wilcoxon test was used to compare the
frequency and severity at visits 2 (4 weeks) and 3 (12
FIG. 1. Status of glottic closure.
TABLE 3. Number of patients scoring voice status as worse,
the same or better since study entry
Turbuhaler1 Nebuhaler1
Voice status Week 4 Week 12 Week 4 Week 12
Worse 4 3 3 3
Same 11 9 21 17
Better 10 13 2 6
450 G. K. CROMPTON ET AL.weeks). Chi-square test was used for comparisons regarding
changes in voice status. For voice laboratory data, the
change from visit 1 to visit 3 was compared between devices
using analysis of variance. The diary measurements were
analysed descriptively using graphical plots of weekly
‘mean’ values of frequency and severity. A treated-per-
protocol (PP) analysis was used. The mean change in
phonation quotient and percentage frequency of perturba-
tion was calculated for patients assessing their voice status
as worse, the same, or better in order to see if an objective
change was related to a subjective change. Also, dose was
correlated with percentage frequency of perturbation,
phonation quotient and questionnaire data to determine
whether subjective and objective measures were related to
dose.
Results
Seventy-two patients were studied. Eight patients were
withdrawn following randomization, 64 completed the
study and 51 were considered evaluable for per protocol
analysis (demographic data, Table 2). Twenty-five patients
received budesonide treatment via Turbuhaler1 and 26
continued pMDI therapy via Nebuhaler1. Of the eight
patients withdrawn, three did not want to continue, one did
not comply with study treatment, two had worsening of
dysphonia (both in the Nebuhaler1 group), one had a sore
mouth (Turbuhaler1) and one developed tiredness, dizzi-
ness and sore mouth (Nebuhaler1). Of the 13 omitted from
the PP analysis, eight reported varying the dose of their
inhaled steroid (four due to an asthma exacerbation andTABLE 2. Demographic data (per protocol analysis) — mean (ra
T
Sex 7
Age (years) 58
Weight (kg) 69
Height (cm) 16
Duration of Asthma (years) 17
Duration of voice problems (years) 3?
FEV1 (l) 1?
FEV1 % predicted 72
FVC1(l) 2?four who misunderstood the dosing regimen), three had an
upper respiratory tract infection during the study, one was
using Turbuhaler1 incorrectly, and in one a diagnosis of
spastic dysphonia was made at laryngoscopy.
LUNG FUNCTION ASSESSMENT
There was no significant change in lung function (FEV1 and
FVC) in either group during the course of the study.
DYSPHONIA QUESTIONNAIRE
Looking at changes from baseline, there was no significant
dierence between the devices for the frequency or severity
of throat irritation, voice problems, huskiness or weakness
after 4 or 12 weeks of treatment. In both groups about 50%
of patients had a decrease in frequency of voice problems
and huskiness (Turbuhaler1 — 12 out of 25; Nebuhaler1
— 14 out of 26). In response to the question as to whether
voice status was worse, the same or better (Table 3), 40% of
the Turbuhaler1 group compared with 8% of the
Nebuhaler1 group stated they were better (P50?02) at 4
weeks. These figures increased for both devices after 12
weeks; 52% for Turbuhaler1 and 23% for Nebuhaler1.
This dierence between treatments was not statistically
significant (P = 0?08).nge)
urbuhaler1 Nebuhaler1
male, 18 female 5 male, 21 female
(21–81) 57 (22–77)
(51–95) 70 (47–121)
2 (150–183) 162 (150–187)
(0?9–51) 21?9 (2?1–57.7)
4 (0?3–12?8) 4?1 (0?3–15?2)
8 (0?5–5?0) 1?6 (0?2–3?4)
?9 (23?1–120?5) 64?4 (9?1–104?1)
7 (1?4–6?2) 2?5 (0?3–4?7)
TABLE 4. Mean laboratory values
Assessment Turbuhaler1 Nebuhaler1
Study entry Week 12 Change Study entry Week 12 Change
Fundamental frequency (Hz) Mean 169 174 5?4 175 175 0?0
SD 35 43 16?9 35 26 18?3
n 24 24 24 23 23 23
Frequency perturbation or jitter Mean 0?87 0?56 70?3 1?06 0?86 70?2
SD 0?66 0?48 0?4 1?4 1?44 0?5
n 24 24 24 23 23 23
Maximum phonation times (s) Mean 8?34 9?56 1?2 9?74 10?37 0?6
SD 4?28 4?92 2?1 3?63 5?4 4?5
n 24 24 24 23 23 23
Phonation quotient Mean 0?40 0?35 70?1 0?30 0?31 0?0
SD 0?24 0?20 0?1 0?12 0?16 0?2
n 23 23 23 22 23 22
%Voiced Mean 96?3 98?3 2?0 96?9 98?6 1?7
SD 4?1 3?1 3?4 6?8 2?5 5?9
n 24 24 24 23 23 23
Semi tone (pitch range) Mean 18?8 20?6 1?4 18?4 17?4 71?0
SD 4?9 4?3 4?2 5?7 6?1 5?5
n 24 22 22 23 22 22
*Dierences between devices were not significant.
TABLE 5. Number of patients showing dierent degrees of
glottic closure at study entry and week 12
Glottic Closure Turbuhaler1 Nebuhaler1
Study
entry
Week
12
Study
entry
Week
12
Complete 9 10 13 12
Irregular 0 0 1 0
Bowing 2 1 0 0
Posterior chink 2 0 2 1
Incomplete 11 13 9 12
*One patient in each group did not have their cords
examined.
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There was no significant dierence between treatment
groups regarding change in voice laboratory assessments
(Table 4).
LARYNGOSCOPIC ASSESSMENTS
Candidiasis or inflammation of the cords was not seen at
entry or after 12 weeks’ treatment. Classification of glottic
closure is shown in Table 5. In the Turbuhaler1 group, two
patients’ glottic closure changed from complete to incom-
plete, and two patients’ glottic closure changed fromincomplete to complete. In the Nebuhaler1 group, five
patients changed from complete to incomplete. There was
no clear association between glottic closure and the
patients’ assessment of voice status.
DIARY CARD DATA
On visual inspection of the graphical plots of weekly ‘mean’
values of frequency and severity of voice problems, there
were no notable dierences between the two devices for any
of the assessments.
SUBJECTIVE VERSUS OBJECTIVE DATA
Regardless of treatment, patients’ subjective assessment of
change in voice status did not relate to change in phonation
quotient or percentage frequency of perturbation.
DOSE OF BUDESONIDE
There were no significant correlations in either group
between dose and percentage frequency of perturbation or
phonation quotient measured at the end of the study.
Discussion
It is the anecdotal impression of many clinicians that
corticosteroid dry powder inhalers are associated with less
voice problems than pMDI with or without a spacer. It is of
452 G. K. CROMPTON ET AL.interest that a significant proportion of patients in this
study thought their dysphonia had improved during the
first 4 weeks of treatment with Turbuhaler1 compared to
the pMDI group, but although 52% of the Turbuhaler1
and 23% of the Nebuhaler1 patients felt that their
dysphonia was better after 12 weeks, this dierence was
not significant and does not support statistically the
findings of other workers (5,6). The lack of a significant
result may have been a function of a small sample size.
Patients selected for this study had established voice
problems, and it is possible that in such patients continua-
tion of inhaled corticosteroid therapy of any kind
perpetuates the problem. A better study design would have
included a period during which inhaled corticosteroids were
withdrawn completely before randomization to allow
recovery of voice function. However, this would have been
dicult in the population of asthmatics chosen, since all
were in need of an inhaled corticosteroid in a daily dose of
800 mg or more, and it can take many weeks for inhaled
corticosteroid-induced dysphonia to improve (4). As this
was an open study, we must also consider that the
improvement may have been partly a placebo eect, in
that since most of the Turbuhaler1 group were originally
using a pMDI, the move onto a new device may have
precipitated an improvement.
The amount of budesonide delivered to the airways by
Turbuhaler1 is greater than that from pMDI (7,8). This
means that more drug passes through the larynx when
Turbuhaler1 is used compared to pMDI, and perhaps it
would have been more appropriate to have reduced the
dose of budesonide in the Turbuhaler1 group. This
approach is supported by Toogood et al. (2), where it was
shown that the problem of dysphonia increased with an
increased dose. As for changing the device, although the
study by Selroos et al. (6) could be criticized, as it compared
retrospective data with clinical events observed prospec-
tively, they found a considerable reduction in the number of
patients with voice problems when Turbuhaler1 treatment
was substituted for pMDI-inhaled corticosteroid treatment
in a group of 154 asthmatic patients. Mouth rinsing was
used after Turbuhaler1 use by the patients reported by
Selroos et al. (6), and by our patients. However, mouth
rinsing is unlikely to prevent dysphonia since it is
impossible to ‘rinse’ the larynx. Indeed, even large volume
spacers, which are beneficial in reducing candidiasis (9,10),
do not protect against dysphonia (3,11).
We were surprised by the voice laboratory assessments
performed at study entry and at 12 weeks, as no correlation
was found between changes in phonation quotient or
percentage frequency of perturbation, and any of the
subjective diary card data. Standard deviations for labora-
tory assessments were relatively large, and a very large
number of patients would have to be studied to have the
power to detect possible dierences. There was also no
correlation between voice symptoms and observed changes
in glottic closure. At the start of the study complete glottic
closure was observed in almost half the patients [22 (43%)].
Only two were found to have vocal cord bowing, and since
so many patients had normal mechanical glottic function in
the absence of any other abnormality, this indicates thatcorticosteroid-induced dysphonia is not always associated
with the ‘characteristic’ abnormality of vocal cord bowing,
as reported by Williams et al. (4). This major dierence
between the two studies could be due to dierent entry
criteria; the Williams study required severe dysphonia,
whilst our study included patients with moderate to severe
dysphonia. Alternatively, it may be that the indirect
fibreoptic laryngoscopy performed in this study was grossly
inaccurate, or that a large proportion of our patients had
dysphonia of psychogenic origin. We do not believe that the
laryngoscopic findings in our study were inaccurate.
In conclusion, this study suggests that voice laboratory
assessments of patients using inhaled corticosteroids and
reporting dysphonia have little or no value in the
investigation of this problem, and there is no correlation
between symptoms, voice laboratory investigations and
laryngoscopic appearances. Lastly, bowing of the vocal
cords was not found to be a ‘characteristic abnormality’
of dysphonia associated with use of inhaled corticoster-
oids.
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